Zobrazeno 1 - 10
of 40
pro vyhledávání: ''
Autor:
Gilberto Lopes
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in th
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Publikováno v:
BMC cancer, 16:712. BioMed Central Ltd.
BMC Cancer
BMC Cancer
Background: Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER-positive/HER2-negative) breast cancer. We
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 228 (2010)
BMC Cancer
BMC Cancer
Background The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recogni
Autor:
Karin Jirström, Donal J. Brennan, William M. Gallagher, Elton Rexhepaj, Michael J. Duffy, Darran P. O'Connor, Sallyann L. O'Brien, Göran Landberg
Publikováno v:
BMC Cancer
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
Background Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indicator in breast cancer. Here, w
Autor:
Taijiro Kosaka, Masahiko Tanabe, Atsushi Arakawa, Hiroshi Sonoue, Fumie Igari, Hideo Shimizu, Koji Senuma, Emi Tokuda, Yoshiya Horimoto, Mitsue Saito
Publikováno v:
BMC Cancer
Background Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. H
Autor:
Jückstock, Julia, Rack, Brigitte, Friedl, Thomas W. P., Scholz, Christoph, Steidl, Julia, Trapp, Elisabeth, Tesch, Hans, Forstbauer, Helmut, Lorenz, Ralf, Rezai, Mahdi, Häberle, Lothar, Alunni-Fabbroni, Marianna, Schneeweiß, Andreas, Beckmann, Matthias W., Lichtenegger, Werner, Fasching, Peter A., Pantel, Klaus, Janni, Wolfgang
Publikováno v:
BMC Cancer
Background Recently, the prognostic significance of circulating tumor cells (CTCs) in primary breast cancer as assessed using the Food-and-Drug-Administration-approved CellSearch® system has been demonstrated. Here, we evaluated the prognostic relev